logo
  

QIWI Reports Pricing Of Public Offering Of 7.97 Mln Class B Shares At $40/ADSs

QIWI plc (QIWI) announced the pricing of public offering of 7.97 million of Class B Shares represented by ADSs at $40.00 per ADSs. The offering is expected to close on or about June 20, 2014.

Out of which, 1.99 million Class B Shares will be sold by the company and 5.98 million Class B Shares will be sold by certain of its shareholders, the company stated.

The underwriters of the offering will have a 30-day option to buy additional 299 thousand Class B Shares from the company and 897 thousand Class B Shares from the selling shareholders at the Offering Price, less underwriting discounts and commissions.

QIWI intends to use offering net proceeds for general corporate purposes. QIWI specified that it will not receive any proceeds from the sale of ADSs by the selling shareholders.

Credit Suisse and VTB Capital are serving as joint book-running managers for the offering. William Blair, Aton and Gazprombank are serving as joint-lead managers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT